Kolkata, West Bengal -- (SBWIRE) -- 10/03/2013 -- CordLife India has now using a novel process cord blood using the upgraded Swiss-made technology Sepax 2 and the extension of their stem cell storage tenure to 25 years. The company is the first stem cell bank in India to have implemented these advancements.

Sepax 2 is an FDA approved fully automated cell separation system that is widely recognized as the industry standard in cord blood banking globally. Almost half of the worldwide processing procedures for cord blood inventory were processed with Sepax 2. The system is one of the most efficient and consistent platforms that can recover as much as 99.46 per cent of cells from a cord blood unit and provides exceptional post-thaw cell viability count.

"This is a critical factor in ensuring a successful stem cell transplant. One other unique feature of Sepax 2 is it processes one cord blood unit at a time in a closed system format, limiting the risk of cross-contamination and sample mix up. As a leading healthcare company in Asia, we are committed to delivering the highest of quality standards in our service and product offerings. Our upgrade to Sepax 2 will help provide our clients with world-class quality cord blood stem cells in the event when a transplant becomes necessary," said Meghnath Roy Chowdhury, managing director, CordLife.

The company has also extended its cord blood and umbilical cord storage tenure to 25 years instead of the usual industry practice of 18 years. This move further demonstrates the company's commitment to be around in India for the long haul for the benefit of their clients.

CordLife and its parent company CordLife Group Limited, have been in the forefront of the industry in Asia for more than 12 years. Cord blood stem cells, obtained from the umbilical cord immediately following birth, are currently used to treat diseases such as leukaemia, lymphoma and thalassemia major. Successful transplants for these indications occur regularly at hospitals both domestically and internationally. To enhance the effectiveness of a cord blood transplant and to avail more medical options for families, CordLife also offers umbilical cord banking service. Using its unique patented technology, CellOptima, it is the only company in the country that can extract Epithelial stem cells and Mesenchymal stem cells from the umbilical cord.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Kolkata, West Bengal -- (SBWIRE) -- 07/29/2013 -- Cordlife Group Limited ("Cordlife", and together with its subsidiaries, the "Group"), a leading cord blood and tissue banking service provider, announced today that its Indian subsidiary, Cordlife Sciences India Pvt. Ltd ("Cordlife India"), has attained accreditation from AABB, an international, not-for-profit association representing individuals and institutions involved in the field of transfusion medicine and cellular therapies. It has been granted the International Certificate of Accreditation for activities relating to the processing, storage and distribution of cord blood.

Mr Jeremy Yee, Executive Director and Chief Executive Officer of Cordlife said, "AABB is the world's gold standard in private cord blood banking, and facilities undergo an intensive accreditation process that includes auditing activities such as client education, processing, testing and storage of clients' precious cord blood units. The Group now has three AABB accredited facilities in Singapore, Hong Kong and India."

Since 1957, AABB has developed voluntary standards for blood bank, blood component collection, processing and transfusion and assessed compliance with these standards, the Code of Federal Regulations and federal guidance documents, through its accreditation program. By assessing the quality and operational systems in place within a facility, the program strives to improve the safety of collecting, processing, testing, distributing and administering blood and blood products.

The initial public offering of Cordlife's shares was sponsored by Prime Partners Corporate Finance Pte. Ltd, who assumes no responsibility for the contents of this release.

Since inception, Cordlife has established a quality system that has been recognised by international accrediting bodies such as AABB and ISO. This is further evidenced by Cordlife's Quality Guarantee introduced in India in 2010, which assures customers of a cord blood unit of suitable match or US$25,000 to defray medical costs if the cord blood unit loses its viability at the point of transplant. In addition to the fact that Cordlife's facility in India is already ISO 9001:2008 certified, the Quality Guarantee is a further testament to its confidence in the reliability of its quality systems.

According to a 10 April 2013 report by Deloitte & Touche Financial Advisory Services Limited ("the Deloitte report"), the 2007–2011 Compound Annual Growth Rate of annual incremental storage units for private cord blood banks is 35% for India. The fast-rising middle class in India are becoming increasingly aware of the benefits of private cord blood banking for their children and seeking better healthcare options for their children.

Mr Yee continued: "While Cordlife continues to expand aggressively, we still remain very focused on delivering the highest quality standards. Transplant physicians are more likely to accept an internationally accredited cord blood unit, compared to a unit which is not. With this AABB accreditation, we are confident of further increasing our share of the private cord blood banking business in the fast growing India market."

ABOUT CORDLIFE GROUP LIMITED
Incorporated in May 2001, Cordlife Group Limited is an established cord blood and tissue banking service provider. Amongst the first private cord blood banks in Asia, Cordlife has established a dominant market leader position in Singapore1. Today, it has the larger market share of the only two private cord blood banks in Singapore. In Hong Kong, it is amongst the three market leaders for private cord blood banks. Cordlife completed the acquisition of the cord blood and cord tissue banking businesses and assets in India, the Philippines and Indonesia from Australia-listed Cordlife Limited in June 2013.

The Group collects, processes, tests, cryopreserves and stores stem cells from the umbilical cord blood of the child at birth, allowing customers to preserve their child's cord blood stem cells for treatment later in his or her life if their child so requires. In March 2011, the Group launched umbilical cord tissue banking service in Hong Kong, offering an additional service that allows customers to collect and store their child's umbilical cord tissue, which is a rich source of mesenchymal and epithelial stem cells and may potentially help repair the body in different ways. In May 2013, Cordlife Technologies Pte Ltd, a wholly-owned subsidiary of Cordlife Group Limited, launched umbilical cord tissue banking service in Singapore. The storage and banking of umbilical cord tissue services provided in Singapore is currently not licensed by the Ministry of Health, Singapore. This service is provided on a research/clinical trial basis.

Cordlife's business model, which allows customers to opt for a one-time lump sum payment, or annual payments until the child reaches maturity (21 years old in Singapore and 18 years old in Hong Kong), provides the Group with a stable pool of recurring cash flow.

In addition, Cordlife, through its collaborative relationships or arrangements with major private hospitals and clinics such as Thomson Medical and Parkway East Hospital, has continued to increase public awareness of its cord blood banking services in Singapore. Overseas, the Group has a 10% direct stake in China Cord Blood Corporation – a top operator in China holding majority shares in the Beijing, Guangdong and Zhejiang Cord Blood Banks, and an approximately 20% share in Shandong Cord Blood Bank.

Cordlife has been accredited since 2005 by AABB (formerly known as the American Association of Blood Banks), an association involved in the field of transfusion medicine and cellular therapies. The Group is one of the first private cord blood banks in Singapore and amongst the first in Hong Kong to have released cord blood units for transplants and other therapeutic use. In Singapore, Cordlife was the first private cord blood bank to release cord blood units for the treatment of cerebral palsy.

Cordlife's track record has won the Group many accolades and awards, including: Best Medical Service Award 2010 by Capital CEO Supreme Brand Awards; Top Pregnant/Baby Products Award 2011 by Pregnancy Magazine; Outstanding Financial Strength Cord Blood Bank 2012 by Quamnet Outstanding Enterprise Awards; Most Popular Brand Award 2010 – The Most Popular Cord Blood Bank by TVB Weekly; and U-Choice Lifestyle Brand Award 2010 by Metroinfo FM99.72. In October 2012, Cordlife was awarded the prestigious SIAS Investors' Choice Awards as runner-up in the "Most Transparent Company Award 2012" New Issues Category.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Kolkata, West Bengal -- (SBWIRE) -- 06/14/2013 -- CordLife India, the largest and most advanced cord blood bank facility in the country, has come up with the Umbilical Cord banking service for the clients. It is considered to be a reliable company that offers different technology of differentiating, isolating, and expanding the two cell lines from the umbilical cord.

Talking about the benefits offered by this technique, a representative of the company stated, "1 in 200 individuals1 may need a hematopoietic stem cells (HSCs) transplant by the age of 70 according to a scientific paper published in 2008. It is once-in-a-life time chance to collect cord blood – a readily available source when needed in the future. 60% higher chance of match versus bone marrow in a family."

The company also ensures the clients that the stem cells of their baby will be processed with the help of the most advanced techniques. The cells can be used for therapies in the future as well. This is one cord blood bank in India that not only offers umbilical cord banking service, but also helps its clients who are mommies to be, to join Cordlife club.

The diseases that are treated with cord blood at this healthcare company include blood cancer, solid tumor, non-malignant blood disorders, immunodeficiency disorders, and metabolic disorders. This healthcare company often shares its latest information on its social media pages available in various social networking sites like Twitter and Google+.

About Cordlife
Cordlife Limited is a leading healthcare company that provides a full suite of cord blood and tissue banking services to expectant parents for the collection, processing and cryopreservation of cord blood stem cells and umbilical cord tissue. The Company is dedicated to offering the highest possibility of successful adult stem cell therapy to give hope and save lives. Listed on the Australian Securities Exchange, Cordlife Limited is well established as the largest network of private stem cell banks across Asia Pacific with state-of-the-art cord blood and tissue processing and cryopreservation facilities in India, Indonesia, the Philippines, Singapore, Hong Kong, and China.

For more information, please visit www.cordlifeindia.com/

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Kolkata, India -- (SBWIRE) -- 04/29/2013 -- Cordlife Limited is the only Stem cell Bank in India that has the technology to extract Epithelial (EpSCs) and Mesenchymal (MSCs) stem cells with immense potential in aiding the repair of injured tissues and organs and aids in treatment of various other diseases. Nonetheless, Cordlife Limited is the only bank that offers stem cell therapy in India with EpSCs extraction.

EpSCs form the soft tissues that connect, support, or surround other structures and organs of the body including cornea, skin, and liver. MSCs are the building blocks of structural tissues of our body such as bone, cartilage, muscle, fibrous tissues and fat. By storing a combination of HSCs, MSCs and EpSCs, you are availing your child the access to growing applications of stem cells and the therapeutic potential.

With growing demand for stem cell banks in India and simultaneously abroad, CordLife Limited brings hundreds of benefits and applications to human life.

"It is truly a once-in-a-life time chance to collect cord blood which helps in treating many diseases when positively needed in future, "

About CordLife Limited
CordLife Limited is a leading healthcare company that provides a full suite of cord blood and tissue banking services to expectant parents for the collection, processing and cryopreservation of cord blood stem cells and umbilical cord tissue. The Company is dedicated to offering the highest possibility of successful adult stem cell therapy to give hope and save lives. Listed on the Australian Securities Exchange, CordLife Limited is well established as the largest network of private stem cell banks across Asia Pacific with state-of-the-art cord blood and tissue processing and cryopreservation facilities in India, Indonesia and the Philippines as well as a network that extends to Singapore, Hong Kong, and China.

To know more visit: http://www.cordlifeindia.com/about-cordlife/contact-us

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Kolkata, West Bengal -- (SBWIRE) -- 04/29/2013 -- Cordlife Limited with its proven expertise and quality gives new dimensions and new definitions to cord blood banking in India. They have got the largest network of private cord blood banks in Asia Pacific and provide state-of-the-art cord blood, tissue processing and cryopreservation facilities in India, Indonesia and the Philippines.

Representative at CordLife Limited stated, "Since our inception, we have established a quality system and proven track record of reliable umbilical cord blood banking services. Our facility in Singapore became the first private cord blood bank in Southeast Asia to be accredited by AABB. We pride ourselves on these stringent standards and guarantee that your baby's cord blood unit will be screened, processed and stored according to the strictest international quality assurance program."

At Cordlife Limited they guarantee their client's wards the peace of mind with assurance of cord blood replacement either at no cost or a compensation of up to US$ 30,000 in case blood loses its viability. Baby's cord blood could be a perfect gift for child's future and for his or her immunity.

With the implementations of best industry practices baby's stem cell extraction is given new definition at Cordlife Limited. Their qualified biotechnologists treat all cord blood samples with equal dedication and with perfection, to provide high-end services.

About CordLife Limited
CordLife Limited is a leading healthcare company that provides a full suite of cord blood and tissue banking services to expectant parents for the collection, processing and cryopreservation of cord blood stem cells and umbilical cord tissue. The Company is dedicated to offering the highest possibility of successful adult stem cell therapy to give hope and save lives. Listed on the Australian Securities Exchange, CordLife Limited is well established as the largest network of private stem cell banks across Asia Pacific with state-of-the-art cord blood and tissue processing and cryopreservation facilities in India, Indonesia and the Philippines as well as a network that extends to Singapore, Hong Kong, and China.

To know more visit: http://www.cordlifeindia.com

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Kolkata, India -- (SBWIRE) -- 04/11/2013 -- CordLife India, the largest and most advanced cord blood bank facility in the country, introduced Umbilical Cord banking to the clients. It is the only company in India that offers novel and patented technology of isolating, differentiating and expanding the two cell lines from the umbilical cord. Their state-of-the-art laboratory is equipped with full processing, testing and cryopreservation capability that guaranties the safe and secure reservation of the umbilical cords.

A representative from the company elaborated the benefits offered by this technique by stating, "1 in 200 individuals1 may need a hematopoietic stem cells (HSCs) transplant by the age of 70 according to a scientific paper published in 2008. It is once-in-a-life time chance to collect cord blood – a readily available source when needed in the future. 60% higher chance of match versus bone marrow in a family."

The company also assures its clients that their baby's stem cells will be processed with the most advanced and proven techniques. The cells will have the ability to be used for therapies in the future. The representative explained working of the process, he said" CordLife uses multiple cryovials to store umbilical cord tissue sections. By storing in cryovials, you have the option to withdraw one cryovial at a time without affecting the viability of the tissue sections in other cryovials."

"The cryovials are further wrapped inside an overwrap bag to further safeguard against cross-contamination. When it comes to umbilical cord blood banking, we always insist on the best so that our clients can have better transplant and cellular therapy outcome," he added further.

The results that stem cells therapy has yielded in previous years are outstanding and with the promising future ahead in this field, it is good to keep Umbilical cord safe in CordLife to have a healthy life through out.

About CordLife
CordLife Limited is a leading healthcare company that provides a full suite of cord blood and tissue banking services to expectant parents for the collection, processing and cryopreservation of cord blood stem cells and umbilical cord tissue. The company is dedicated to offering the highest possibility of successful adult stem cell therapy to give hope and save lives.

To know more about their services please visit http://www.cordlifeindia.com .

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Kolkata, India -- (SBWIRE) -- 03/13/2013 -- Cordlife Quality Guarantee gives their client a complete peace of mind as they assure of a cord blood replacement at no cost or a compensation of up to US$30,000, in case the cord blood loses its viability at the point of transplant. Nonetheless, banking of umbilical cord with Cordlife is once in a life time chance to collect cord blood which should not be wasted.

Regarding its mission and values, a representative for the organization says, "Cordlife India is the largest and most advanced cord blood facility in the country, with a storage capacity of up to 150,000 cord blood units. The state-of-the-art laboratory with full processing, testing and cryopreservation capabilities is equipped with continuous power back-up as well as the most-up-to-date security and surveillance systems."

He also claims that the building is specially designed to withstand any natural calamity; thus, located in Kolkata and officially launched by Singapore Senior Minister and former Prime Minister Mr Goh Cho Tong, Cordlife India has become the only licensed organization for cord life banking. It is the first and the only company in India to introduce the novel and patented technology of isolating, differentiating and expanding the two cell lines from the umbilical cord.

Cordlife with this technology assures its clients that their baby's stem cells have been processed with the most current state of the art techniques and these cells have the ability to be used for therapies in the future. For its diligence and commitment to work, Cordlife was awarded with the prestigious 'Technology Pioneer' status by the Geneva-based World Economic Forum.

About Cordlife
CordLife Limited is a leading healthcare company that provides a full suite of cord blood and tissue banking services to expectant parents for the collection, processing and cryopreservation of cord blood stem cells and umbilical cord tissue. The company is dedicated to offering the highest possibility of successful adult stem cell therapy to give hope and save lives. Listed on the Australian Securities Exchange, CordLife Limited is well established as the largest network of private stem cell banks across Asia Pacific with state-of-the-art cord blood and tissue processing and cryopreservation facilities in India, Indonesia and the Philippines as well as a network that extends to Singapore, Hong Kong, and China.

To know more visit: http://www.cordlifeindia.com/enrollment/enrollment-process

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Kolkata, West Bengal -- (SBWIRE) -- 02/22/2013 -- Cord blood banking in India, also called "placental blood," is blood that remains in the umbilical cord and placenta following the birth of a baby. It is a unique and one of its own kind of facility provided in India. During pregnancy, the umbilical cord functions as a lifeline between mother and child. After a baby's delivery, the cord blood present in the umbilical cord could offer future hope for the child or other members of the family.

At CordLife India, they offer hope for a child and for the family members to fight a number of fatal diseases in the future. The procedure only takes about three minutes and does not alter the birthing process in any way. It can be done with either a vaginal or caesarean delivery.

The collection, processing and storage of cord blood banking involve immediately clamping and cutting the cord after the delivery of a baby. The caregiver then collects the umbilical cord blood by inserting a needle into the cord vein, and drains the same into a blood bag.

Since their inception, CordLife India has established a quality system and proven track record and has emerged as a reliable cord blood banking services provider. Their capability was recognized when their facility in Singapore became the first private cord blood bank in Southeast Asia to be accredited by AABB, the world's gold standard in private cord blood banking.

About CordLife Limited
CordLife Limited is a leading healthcare company that provides a full suite of cord blood and tissue banking services to expectant parents for the collection, processing and cryopreservation of cord blood stem cells and umbilical cord tissue. The company is dedicated to offering the highest possibility of successful adult stem cell therapy to give hope and save lives. Listed on the Australian Securities Exchange, CordLife Limited is well established as the largest network of private stem cell banks across Asia Pacific with state-of-the-art cord blood and tissue processing and cryopreservation facilities in India, Indonesia and the Philippines as well as a network that extends to Singapore, Hong Kong, and China. To know more visit: http://www.cordlifeindia.com.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Kolkata, West Bengal -- (SBWIRE) -- 02/15/2013 -- CordLife India, a leading healthcare company that provides a full suite of cord blood and tissue banking, offers quality guarantee on its cord blood banking facilities. Cord Life's reliability and confidence is embodied in its quality guarantee protecting all clients. Cord Life India is the only healthcare center in India that provides quality guarantee on cord blood banking.

The quality guarantee gives peace of mind as it assures of cord blood replacement at no cost or a compensation of up to US $30,000 if the cord blood loses its viability at the point of transplant. The company's in-depth knowledge in stem cell banking practices and standards is well-recognized by numerous world-class quality standard organizations as well as country regulators on the Asia Pacific region.

Cord blood banking has gained popularity in India in the recent years. CordLife India targets to secure every baby's future. The company's in-depth knowledge of umbilical cord banking practices and standards is well-known in numerous world-class quality standard organizations as well as country regulators in Asia-Pacific region.

In 2007 Cord Life India was bestowed with the prestigious "Technology Pioneer" title by the World Economic Forum which further validated the Company's outstanding performance in the industry. Only Cord Life has the technology to extract EpSCs from the baby's umbilical cord.

Listed on Australian Securities Exchange, CordLife Limited is well-established as the largest network of private stem cell banks across Asia-Pacific. Its state-of-the-art cord blood and tissue-processing and cryopreservation facilities are available in India, Indonesia and the Philippines as well as a network that extends to Singapore, Hong Kong and China.

About CordLife India
CordLife India is a majority-owned subsidiary of CordLife Limited, a company listed on the Australian Securities Exchange. A winner of Technology Pioneer award conferred by the World Economic Forum, CordLife has accumulated more than 10 years of experience in stem cell processing and cryopreservation. CordLife Limited owns and operates 3 state-of-the-art stem cell processing and cryopreservation facilities in India, Indonesia and the Philippines along with a network extending to other full-fledged facilities in Singapore, Hong Kong and Mainland China.

For more information visit http://www.cordlifeindia.com/

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

West Bengal, India -- (SBWIRE) -- 02/15/2013 -- Cord blood and tissue banking service provider Cordlife Group posted a net profit of S$5.6 million for its fiscal second quarter, boosted by a one-time disposal gain of $2.7 million.

Excluding the disposal of its 10 per cent interest in China-based stem cell company, China Stem Cells (South) Company, Cordlife's underlying net profit grew over 50 per cent to S$3 million.

Revenue for the quarter rose 24 per cent to S$8.8 million.

Cordlife attributed the higher revenue largely to successful marketing efforts to educate expectant parents on the benefits of its cord blood banking services.

Going forward, the group is optimistic that it could benefit from policies to boost fertility and birth rates in Singapore.

The firm said the extension of Child Development Accounts, as well as the higher Baby Bonus, will allow more parents to afford to store their children's cord blood stem cells as an additional medical treatment alternative.

Jeremy Yee, executive director and CEO of Cordlife Group, said: "The Population White Paper was a very interesting one.

"What we look at, at the end of the day, is the fact that the government essentially is going to spur more investment by putting in more infrastructure in place so that the population can grow.

"More incentives have been given to parents to have more children. So all these are positives."

Cordlife's shares closed on Thursday almost 5 per cent higher at 66 cents.Visit http://www.cordlifeindia.com/ for more info.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

West Bengal, India -- (SBWIRE) -- 12/18/2012 -- CordLife India, the largest cord blood bank in India has now become a listed company in Singapore Stock Exchange. Offering the most advanced cord blood banking facility in India, it gives peace of mind to customers as it assures them about a cord blood replacement at no cost or compensation of up to US $ 30000, should the blood loses its viability when being transplanted!

CordLife India preserves cord blood with a cord blood storage capacity for up to 150,000 cord blood units. At Cordlife India, they target to secure every baby's future with stem cell banking. The state of the art laboratory with full processing, testing and cryopreservation capabilities is equipped with continuous power back-up as well as the most up to date security and surveillance.

The organization claims that banking of umbilical cord safeguards the life of the baby. It is once-in-a-life time chance to collect cord blood – a readily available source when needed in the future. CordLife Limited is a leading healthcare company that provides a full suite of cord blood storage and tissue banking services to expectant parents for the collection, processing and cryopreservation of cord blood stem cells and umbilical cord tissue.

The Company is dedicated to offering the highest possibility of successful adult stem cell therapy to give hope and save lives. Listed on the Australian Securities Exchange, CordLife Limited is well established as the largest network of private stem cell banks across Asia Pacific with state-of-the-art cord blood and tissue processing and cryopreservation facilities in India, Indonesia and the Philippines as well as a network that extends to Singapore, Hong Kong, and China.

About CordLife India
CordLife India is the largest and most advanced cord blood bank facility in the country, with a storage capacity of up to 150,000 cord blood units. The state-of-the-art laboratory with full processing, testing and cryopreservation capabilities is equipped with continuous power back-up as well as the most-up-to-date security and surveillance systems. Located in Kolkata and officially launched by Singapore Senior Minister and former Prime Minister Mr Goh Chok Tong, CordLife India is licensed by the Drug Controller General of India to collect cord blood units from all Indian states and cities.

To know more visit: http://www.cordlifeindia.com

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

West Bengal, India -- (SBWIRE) -- 12/18/2012 -- CordLife India, the largest cord blood bank in India has launched new cord blood bank facility. The Advanced Cord Blood Facility with Quality Assurance from CordLife is a facility which stores umbilical cord blood for future use.

The collection, processing and storage of cord blood banking include immediately clamping and cutting the cord after the delivery of a baby. The caregiver then collects the umbilical cord blood by inserting a needle into the cord vein, and drains the same into a blood bag.

Since their inception, CordLife India has established a quality system and proven track record and has emerged as a reliable cord blood banking services provider. Their capability was recognized when their facility in Singapore became the first private cord blood bank in Southeast Asia to be accredited by AABB, the world's gold standard in private cord blood banking.

The winning expertise from Singapore was transferred to other CordLife facilities in Indonesia, Philippines, Hong Kong and now to India. Now, it has attained accreditation and certifications from various organizations and regulators that set standard for efficiency and quality in cord blood banking around the world.

CordLife prides on stringent standards and guarantee that baby's cord blood stem cell unit will be screened, processed and stored according to the strictest international quality assurance program. Transplant physicians are more likely to accept an internationally accredited cord blood unit, compared to a unit which is not.

About CordLife India
CordLife India is the largest and most advanced cord blood bank facility in the country, with a storage capacity of up to 150,000 cord blood units. The state-of-the-art laboratory with full processing, testing and cryopreservation capabilities is equipped with continuous power back-up as well as the most-up-to-date security and surveillance systems. Located in Kolkata and officially launched by Singapore Senior Minister and former Prime Minister Mr Goh Chok Tong, CordLife India is licensed by the Drug Controller General of India to collect cord blood units from all Indian states and cities.

To know more visit: http://www.cordlifeindia.com

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Kolkata, West Bengal -- (SBWIRE) -- 10/07/2012 -- CordLife India, the largest cord blood bank in India, offers the most advanced cord blood banking facility that is protected by The CordLife Quality Guarantee. CordLife quality guarantee gives peace of mind as they assure their customers a cord blood replacement at no cost or compensation of up to US $ 30000, should the blood lose its viability at a point of transplant. CordLife India offers the preservation of cord blood with a cord blood storage capacity for up to 150,000 cord blood units. At Cordlife India, they target to secure every baby's future with stem cell banking. The state of the art laboratory with full processing, testing and cyropreservation capabilities is equipped with continuous power back-up as well as the most up to date security and surveillance.

Spokesperson of Cordlife stated, "Your baby's cord blood could turn out to be the most precious gift to your child. That is why we have it protected by the CordLife Quality Guarantee, the only such guarantee in India. CordLife Quality Guarantee gives you peace of mind as we assure you of a cord blood replacement at no cost or a compensation of up to US$30,000, if the cord blood loses its viability at the point of transplant."

An umbilical cord blood bank renders as a storage facility to the donors, who are eager to preserve cord blood stem cells. Cord blood also called placenta blood, is blood that remains in the umbilical cord and placenta following birth of a baby. It is a rich source of haematopoietic stem cells (HSCs), which are primarily responsible for replenishing blood and regenerating the immune system. Cord blood banking is a facility which stores umbilical cord blood for future use. The collection, processing and storage of cord blood banking include immediately clamping and cutting the cord after the delivery of a baby. The caregiver then collects the umbilical cord blood by inserting a needle into the cord vein, and draining the blood into either a blood bag.

By preserving a baby's stem cells through cord blood banking, the baby will be ensured to have a guaranteed source of perfectly matched cells that can help the child during unfortunate events. This procedure is painless and risk-free to both mother and baby. It takes about 3 minutes and does not alter the birthing process in any way. However, the final decision whether the cord blood collection should continue will always reside with the caregiver whose first priority is the safety of mother and baby.

Along with their associates, Cordlife's in-depth knowledge of the business is recognized by many world-class gold standards and government bodies such as the American Association of Blood Banks (AABB), International Organization for Standardization (ISO) and numerous government regulators. Their stringent quality system helps ensure that every baby's stem cells are carefully processed and cryopreserved using rigorous protocols. To know more about the company log on to http://www.cordlifeindia.com

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Kolkata, West Bengal -- (SBWIRE) -- 06/05/2012 -- The long wait finally comes to an end; a bundle of joy has been welcomed by the actress Shilpa Shetty and her husband Raj Kundra as they are the proud parents of their first baby boy. The actress's husband informed the media that the mother and child are doing absolutely well and the family is ecstatic.

Being responsible and well informed parents, they decided to store their baby's stem cells with Cordlife India, Asia's largest stem cell banking company and have decided to opt for best available plan where stem cells are expanded up to 1000 million for ready use.

Shilpa Shetty has excelled in every field with equal grace, be it as an actress or an entrepreneur. Meghnath Roy Chowdhury, MD, CordLife, said: "We would like to congratulate the couple on this new role and wish them all the best for future. Becoming a parent for the first time is truly a joyous occasion. We, at Cord life, have assured and taken care of that anxiety by banking her baby's stem cell with us."

Notes to the Editor
CordLife India is a majority owned subsidiary of CordLife Limited, a company listed on the Australian Securities Exchange. A winner of technology Pioneer Award, CordLife has accumulated more than 10 years of experience in stem cell processing and cryopreservation. Umbilical Cord Blood, also called Cord Blood which is a rich source of haematopoietic stem cells, is the blood left in the umbilical cord and placenta after the baby is born. The umbilical cord blood is rich source of stem cells. Stem cells are building blocks of various organs and tissues of the body. During pregnancy, the umbilical cord functions as a lifeline between the baby and the mother. Cord blood Banking allows early treatment of the diseases like Parkinson's, Schizophrenia, Alzheimer's and cancer to name a few. As the list of Stem cells treatable diseases continues to grow at a rapid is pace, stem cell banking in India is gaining popularity.

About CordLife India
CordLife India is the largest and most advanced cord blood facility in the country, with a storage capacity of up to 150,000 cord blood units. The state-of-the-art laboratory with full processing, testing and cryopreservation capabilities is equipped with continuous power back-up as well as the most-up-to-date security and surveillance systems. Located in Kolkata and officially launched by Singapore Senior Minister and former Prime Minister Mr Goh Chok Tong, CordLife India is licensed by the Drug Controller General of India to collect cord blood units from all Indian states and cities. To know more click http://www.cordlifeindia.com

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm